ELEgor S. Larin

Egor S. Larin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Egor S. Larin has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Direct and indirect costs associated with state of health in patients receiving home-based respiratory support and oxygen therapy

    by M.V. Avxentyeva, S.N. Avdeev, D.V. Nevzorova, K.A. Krokhin, E.S. Larin, A.O. Bykov, G.S. Nuralieva, V.V. Tkachenko, I.S. Krysanov, V.S. Krysanova

    Objective. To assess direct and indirect costs caused by state of health of patients suffering from chronic respiratory failure (CRF) and receiving respiratory support and oxygen therapy (RSOT) at home but not directly related to participation of patients in the study (i.e., with provision of RSOT). Material and methods. We analyzed direct medical, direct non-medical and indirect costs caused by state of health of patients suffering from CRF and receiving RSOT at home, but not directly related to participation of patients in the study (i.e., with provision of RSOT). We extracted data from patients’ diaries and individual registration cards. In accordance with study protocol, these diaries and cards contained information about medical and social assistance, purchase of medical devices, temporary disability with indication of funding source (compulsory medical insurance system (CMI) or personal funds of patients and their families). Costs of medical care at the expense of CMI were based on tariffs and standards of financial expenses in Moscow. Costs incurred from personal funds were received from diaries. Direct non-medical costs included transportation costs, professional care at home, and payments related to temporary disability. Indirect costs were estimated as losses of gross domestic product (GDP) due to temporary disability of patients of working age. Cost data was collected and processed in subgroup of 65 patients (66.3% of 98 participating in the study). Total costs and weighted average costs per a patient were determined for study period (8.7 months) and calculated on annual basis. Results. Total costs for the entire subgroup throughout study period amounted to RUB 42.6 million, including RUR 6.4 million (14.9%) of direct medical costs, RUB 9.8 million (23.0%) of direct non–medical costs and RUB 26.5 million (62.1%) of indirect costs as GDP losses. Maximum share accounted to inpatient medical care in the structure of direct medical costs. About 9% of direct medical expenses and 38% of direct non-medical expenses were paid from personal funds. Weighted mean cost per a patient per year was as follows: direct medical costs — RUB 34.2 thousand; direct non–medical costs — RUB 200.9 thousand, indirect costs — RUB 642.9 thousand. Conclusion. Health status in patients with chronic respiratory failure receiving respiratory support and oxygen therapy at home represents a significant economic burden for society and state, primarily due to indirect costs associated with disability of working-age patients. These data may be used to analyze budgetary impact of medical interventions in this patient group.

  • Costs of home-based respiratory support and oxygen therapy

    by S.N. Avdeev, D.V. Nevzorova, M.V. Avxentyeva, E.S. Larin, A.N. Komarov, I.S. Krysanov, A.O. Bykov, G.S. Nuralieva, B.E. Pervozvanskiy, V.V. Tkachenko, et al.

    Objective. To assess the direct costs associated with home-based respiratory support and oxygen therapy (RSOT). Material and methods. The study included two stages: prospective follow-up of patients receiving home-based RSOT and economic analysis of results. There were 98 patients (mean age 61 years, 56.9% men) divided into 3 groups depending on home-based RSOT: invasive mechanical ventilation (IMV) — 8 (8.2%), non-invasive ventilation (NIV) — 43 (43.9%) and long-term oxygen therapy (LTOT) — 47 (47.9%). Direct costs of home-based RSOT were estimated. Results. The weighted average monthly expenses per patient with chronic respiratory failure (CRF) requiring RSOT at home were RUR 115.046 (95% CI: RUR 120.374 — 109.717) for IMV, RUR 39.905 (95% CI: RUR 44.336 — RUR 35.473) for NIV and RUR 10.518 (95% CI: RUR 11.128 — RUR 9.909) for LTOT. Most of these costs were related to provision of necessary equipment. Conclusion. Direct costs for home-based RSOT decrease sequentially from IMV to NIV and LTOT.

  • Open Access

    Single-point multicenter survey of using antimicrobial drugs in the ICUs of Russian multidisciplinary hospitals: results of the Global-PPS 2022 project

    by Yu. A. Belkova, A. A. Kurkova, S. A. Rachina, R. S. Kozlov, E. N. Bochanova, E. V. Elokhina, S. K. Zyryanov, O. V. Ignatenko, E. S. Larin, G. G. Melkonyan, et al.

    Introduction. The marked increase in the resistance of infectious disease pathogens to antimicrobial drugs (AMDs), especially in intensive care units (ICUs), poses a threat to healthcare systems worldwide. This leads to adverse consequences: medical, social and economic. The objective was to evaluate the practice of AMDs using in the ICUs of Russian multidisciplinary hospitals based on its compliance with quality indicators.Materials and Methods. Single-point survey of AMDs using was conducted in 37 ICUs of various types in 12 multidisciplinary hospitals in different cities of the Russian Federation (Krasnoyarsk, Moscow (4 centres), Omsk, Saratov, Smolensk (2 centres), Tomsk, Yakutsk and Yaroslavl). The study was conducted in accordance with the protocol of international Global-PPS project from September to December 2022. The object of the study was the medical records of patients who received systemic AMDs for preventive or curative purposes. The practice of AMDs using was studies as well as the assessment of the prescription compliance with the quality indicators.Results. The survey included 501 patients of whom 314 (62.7%) received systemic AMDs. The frequency of AMDs prescription ranged from 24% in cardiac ICUs to 86.9% in surgical ICUs and reached 100% in paediatric departments. The vast majority of drugs were used for therapeutic purposes (74.3%–89.3%) and were prescribed for the treatment of nosocomial infections (71.6% on the average). Carbapenems (20.6%), third-generation cephalosporins (13.1%) and fluoroquinolones (11.6%) prevailed in the structure of prescriptions.Conclusion. The following accuracies in AMDs using were identified during our study: low frequency of etiotropic therapy, inappropriate duration of perioperative antibiotic prophylaxis and relatively low frequency of planning the duration of therapy. These accuracies provide an opportunity to optimize the practice of using drugs of this group in ICUs of hospitals participating in the study.


  • Open Access

    Respiratory support and oxygen therapy at home: Clinical results of the prospective observatory study

    by S. N. Avdeev, D. N. Nevzorova, G. E. Ivanova, G. S. Lebedev, N. A. Suponeva, M. V. Avxentyeva, R. I. Shaburov, E. S. Larin, A. N. Komarov, G. N. Levitsky, et al.

    Introduction. Respiratory diseases are number one in the structure of general morbidity of the population of the Russian Federation. The main complication of respiratory diseases is respiratory failure, which may be treated with long-term oxygen therapy (LTOT) and respiratory support (RS): non-invasive mechanical lung ventilation (NIV) and invasive mechanical lung ventilation (IV). International medical experience indicates a widespread enough implementation of respiratory support and oxygen therapy at home (RS and OT at home) for patients including whose requiring palliative medical care.Aim. The purpose of the study was to evaluate the clinical results of implementation of respiratory support and oxygen therapy at home.Materials and methods. The study included 98 patients with chronic respiratory failure (CRF). All patients used RS and OT at home according to the Study Protocol. All patients were divided into 3 groups: LTOT - 47 patients, NIV in combination or with-out LTOT - 43 patients, IV in combination or without LTOT - 8 patients. The estimated parameters of the patients' condition were measured at the initiating visit and three subsequent control sessions. The planned duration of the Study was 9 months.Results. During the Study, a statistically significant decrease in the severity of symptoms of respiratory failure was noted (CAT and mMRC scales) as well as an improvement in the quality of life and the general condition of the patient (SF-36 questionnaire and Karnovsky scale). During the study, 38 patients required hospitalization: in 8 cases hospitalization was associated with an exacerbation of CRF. The number of successful outcomes was 87 cases.Conclusion. The Study showed that RS and OT at home is an effective and safe medical technology for patients with CFR, which reduces the manifestation of symptoms, improves the quality of life, reduces the number of hospitalizations associated with exacerbation of respiratory failure, reduces mortality, and demonstrates the effectiveness of using a modern respiratory equipment at home, as well as telemedicine technologies.


  • Risk factors of colonization and diversity of clinically significant carbapenemases in gut microbiota of ICU patients: a single-center prospective observational study

    by A.O. Bykov, E.M. Shifman, D.N. Protsenko, S.V. Yakovlev, B.Z. Belotserkovskiy, O.G. Ni, A.N. Kruglov, A.A. Bryleva, M.I. Matyash, E.S. Larin

    Background. Carbapenem-resistant Enterobacteriaceae have a major impact on ICU-stay and treatment outcomes. Objective. To identify the risk factors of colonization by CPE (carbapenemase-producing Enterobacterales) in ICU patients. Material and methods. We enrolled 94 ICU patients between November 2020 and January 2021 and divided then into 3 groups: group 1 (n=63) — all patients not colonized by CPE, group 2 (n=31) — colonized upon admission, group 3 (n=31) — colonized after 5-day ICU-stay. All patients underwent microbiological and molecular genetic testing via real-time PCR (AmpliSens MDR MBL-FL and AmpliSens MDR KPC/OXA-48-FL reagent kits) of rectal smear samples. Results. We found CPEs in rectal smear samples that mainly released carbapenemases OXA-48, NDM, KPC and their combinations. Pre-hospital risk factors for intestinal colonization by CPE were identified: male gender (OR=0.28, CI 95% [0.11, 0.74], p=0.010), hospital-stay within previous 3 months (OR=4.22, CI 95 % [1.38; 12.9], p=0.011) and previous antimicrobial therapy (OR=2.23, CI 95% [0.76; 6.54], p=0.145). There were the following risk factors after 5-day hospital-stay: primary colonization (OR=15.64, CI 95% [4.64; 52.73], p<0.0001), female gender (OR=2.51, CI 95% [0.96, 6.56], p<0.059), age (OR=0.969, CI 95% [0.931; 1.007], p=0.112), use of vasopressors (OR=27.11, CI 95% [2.43; 302.11], p=0.007), CRP (OR=0.997, CI 95% [0.992; 1.001], p=0.162), central venous catheter (OR=3.56, CI 95% [1.36; 9.30], p=0.010), proton pump inhibitors (OR 0.38, CI 95% [0.13; 1.11], p=0.077). Conclusion. Early detection of CPE and carbapenemases and their monitoring are necessary to improve the effectiveness of antimicrobial therapy in ICU patients.


  • Open Access

    Diagnosis and antibiotic therapy of nosocomial pneumonia in adults: from recommendations to real practice. A review

    by Svetlana А. Rachina, Ludmila V. Fedina, Marina V. Sukhorukova, Igor N. Sychev, Egor S. Larin, Abdulbari A. Alkhlavov

    Nosocomial pneumonia is a healthcare-associated infection with significant consequences for the patient and the healthcare system. The efficacy of treatment significantly depends on the timeliness and adequacy of the antibiotic therapy regimen. The growth of resistance of gram-negative pathogens of nosocomial pneumonia to antimicrobial agents increases the risk of prescribing inadequate empirical therapy, which worsens the results of patient treatment. Identification of risk factors for infection with multidrug-resistant microorganisms, careful local microbiological monitoring with detection of resistance mechanisms, implementation of antimicrobial therapy control strategy and use of rational combinations of antibacterial drugs are of great importance. In addition, the importance of using new drugs with activity against carbapenem-resistant strains, including ceftazidime/aviabactam, must be understood. This review outlines the current data on the etiology, features of diagnosis and antibacterial therapy of nosocomial pneumonia.